Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology
-$0.03 today
- Market cap
- $372.57M
- Beta
- 1.14
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.70
Volume 0.17M
Average 0.97M
INDP Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Indaptus Therapeutics, Inc.NASDAQ: INDP
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $5.23M (cash outflow) rose 585.5% year over year, ahead of the -251.2% change in trailing-twelve-month accounts payables.
Context
- Accounts payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +585.5% holds above the trailing-twelve-month pace of -251.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 2.85M USD
- Year-over-year change
- +501.0%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.85M | +501.0% |
| FY2024 | 2024-12-31 | 474.06K | +169.7% |
| FY2023 | 2023-12-31 | (680.52K) | +41.1% |
| FY2022 | 2022-12-31 | (1.15M) | +72.7% |
| FY2021 | 2021-12-31 | (4.24M) | — |
Accounts Payables vs competitors
How INDP compares with its peers on the latest reported figures
- INDP's LTM Mar 2026 accounts payables of $1.44M is the largest of the 2 companies compared; the peer median is $610.35K.
- Its year-over-year change of -251.2% is the lowest of 2, against a peer median of +2356.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.44M | -251.2% | — | — | |
| LTM Jun 2026 | $610.35K | +2356.6% | — | — | |
| Peer median (excluding INDP) | $610.35K | +2356.6% | — | — | |
Competitors are the stored peer set for INDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.71M) | (14.32M) | (15.42M) | (15.02M) | (20.85M) |
| Depreciation & Amortization | 1.4K | 1.78K | 1.28K | 735 | 0 |
| Deferred Income Tax | (5.75M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.51M | 2.96M | 2.97M | 2.31M | 1.36M |
| Change in Working Capital | (5.09M) | (1.58M) | (518.07K) | 392.26K | 3.51M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.24M) | (1.15M) | (680.52K) | 474.06K | 2.85M |
| Other Working Capital | (854.15K) | (425.59K) | 162.45K | (81.8K) | 665.3K |
| Other Non-Cash Items | 5.75M | (134.16K) | (430.99K) | 0 | 1.15M |
| Operating Cash Flow | (11.29M) | (13.08M) | (13.41M) | (12.32M) | (14.82M) |
| Capital Expenditures | (3.85K) | (172.56K) | 0 | 0 | (4) |
| Acquisitions (Net) | 451.6K | 172.56K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (29.6M) | (6.86M) | 0 | 0 |
| Sales of Investments | 0 | 13M | 24M | 0 | 0 |
| Other Investing Activities | 0 | 172.56K | 0 | 0 | 0 |
| Investing Cash Flow | 447.75K | (16.43M) | 17.14M | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 5.71M |
| Common Stock Issued | 5M | 0 | 0 | 5.51M | 11.83M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 43.34M | 0 | 0 | (762.7K) | 0 |
| Financing Cash Flow | 48.34M | 0 | 0 | 4.75M | 17.54M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.49M | (29.51M) | 3.74M | (7.58M) | 2.72M |
| Free Cash Flow | (11.29M) | (13.25M) | (13.41M) | (12.32M) | (14.82M) |
Indaptus Therapeutics, Inc.
NASDAQ:INDP
Intrinsic Alpha fair value
Locked
Current Price
$3.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.